It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
NEMO is a ubiquitin-binding protein which regulates canonical NF-κB pathway activation in innate immune signaling, cell death regulation and host-pathogen interactions. Here we identify an NF-κB-independent function of NEMO in proteostasis regulation by promoting autophagosomal clearance of protein aggregates. NEMO-deficient cells accumulate misfolded proteins upon proteotoxic stress and are vulnerable to proteostasis challenges. Moreover, a patient with a mutation in the NEMO-encoding IKBKG gene resulting in defective binding of NEMO to linear ubiquitin chains, developed a widespread mixed brain proteinopathy, including α-synuclein, tau and TDP-43 pathology. NEMO amplifies linear ubiquitylation at α-synuclein aggregates and promotes the local concentration of p62 into foci. In vitro, NEMO lowers the threshold concentrations required for ubiquitin-dependent phase transition of p62. In summary, NEMO reshapes the aggregate surface for efficient autophagosomal clearance by providing a mobile phase at the aggregate interphase favoring co-condensation with p62.
Selective autophagy helps to degrade aggregated proteins accumulating in neurodegenerative diseases. Here, the authors show that NEMO, a ubiquitin binding protein previously linked to innate immune signaling, is recruited to misfolded proteins and promotes their autophagic clearance by forming condensates with the autophagy receptor p62.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
















1 Ruhr University Bochum, Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Bochum, Germany (GRID:grid.5570.7) (ISNI:0000 0004 0490 981X)
2 Ruhr University Bochum, Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Bochum, Germany (GRID:grid.5570.7) (ISNI:0000 0004 0490 981X); Ruhr University Bochum, Department Biochemistry of Neurodegenerative Diseases, Institute of Biochemistry and Pathobiochemistry, Bochum, Germany (GRID:grid.5570.7) (ISNI:0000 0004 0490 981X)
3 Ruhr University Bochum, Department of Neurology, St Josef Hospital, Bochum, Germany (GRID:grid.5570.7) (ISNI:0000 0004 0490 981X)
4 Ruhr University Bochum, Department Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Bochum, Germany (GRID:grid.5570.7) (ISNI:0000 0004 0490 981X); Cluster of Excellence RESOLV, Bochum, Germany (GRID:grid.517297.f)
5 Ruhr University Bochum, Department Biochemistry of Neurodegenerative Diseases, Institute of Biochemistry and Pathobiochemistry, Bochum, Germany (GRID:grid.5570.7) (ISNI:0000 0004 0490 981X)
6 Max Planck Institute of Biochemistry, Department of Cellular Biochemistry, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X)
7 Ruhr University Bochum, Analytical Chemistry II, Faculty of Chemistry and Biochemistry, Bochum, Germany (GRID:grid.5570.7) (ISNI:0000 0004 0490 981X)
8 Cluster of Excellence RESOLV, Bochum, Germany (GRID:grid.517297.f); Ruhr University Bochum, Analytical Chemistry II, Faculty of Chemistry and Biochemistry, Bochum, Germany (GRID:grid.5570.7) (ISNI:0000 0004 0490 981X)
9 Technical University of Denmark, Department of Biotechnology and Biomedicine, Kongens Lyngby, Denmark (GRID:grid.5170.3) (ISNI:0000 0001 2181 8870)
10 Ruhr University Bochum, Department of Neurology, St Josef Hospital, Bochum, Germany (GRID:grid.5570.7) (ISNI:0000 0004 0490 981X); Klinikum Dortmund, University Witten/Herdecke, Department of Neurology, Dortmund, Germany (GRID:grid.473616.1) (ISNI:0000 0001 2200 2697)
11 Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neuropathology, Charité - Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
12 Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neuropathology, Charité - Universitätsmedizin Berlin, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Ludwig-Maximilians University, Center for Neuropathology and Prion Research, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
13 University of Lübeck, Institute of Neurogenetics, Lübeck, Germany (GRID:grid.4562.5) (ISNI:0000 0001 0057 2672)
14 Forschungszentrum Jülich, Ernst-Ruska Centre for Microscopy and Spectroscopy with Electrons (ER-C-3/Structural Biology), Jülich, Germany (GRID:grid.8385.6) (ISNI:0000 0001 2297 375X); Forschungszentrum Jülich, Institute for Biological Information Processing (IBI-6/Cellular Structural Biology), Jülich, Germany (GRID:grid.8385.6) (ISNI:0000 0001 2297 375X)
15 Forschungszentrum Jülich, Ernst-Ruska Centre for Microscopy and Spectroscopy with Electrons (ER-C-3/Structural Biology), Jülich, Germany (GRID:grid.8385.6) (ISNI:0000 0001 2297 375X); Forschungszentrum Jülich, Institute for Biological Information Processing (IBI-6/Cellular Structural Biology), Jülich, Germany (GRID:grid.8385.6) (ISNI:0000 0001 2297 375X); Heinrich Heine University, Department of Biology, Düsseldorf, Germany (GRID:grid.411327.2) (ISNI:0000 0001 2176 9917)
16 Ludwig-Maximilians-Universität München, Munich Cluster for Systems Neurology, Faculty of Medicine, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
17 University Medical Center Hamburg-Eppendorf, Institute of Neuropathology, Hamburg, Germany (GRID:grid.13648.38) (ISNI:0000 0001 2180 3484)
18 Max Planck Institute of Biochemistry, Department of Cellular Biochemistry, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (GRID:grid.452617.3)
19 Gladstone Institutes, Gladstone Institute of Neurological Disease, San Francisco, USA (GRID:grid.249878.8) (ISNI:0000 0004 0572 7110); University of California, Department of Neurology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
20 University of California, Department of Neurology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California San Francisco, Weill Institute for Neurosciences, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
21 University of California, Department of Neurology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811); University of California, Department of Pathology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
22 Ruhr University Bochum, Department Biochemistry of Neurodegenerative Diseases, Institute of Biochemistry and Pathobiochemistry, Bochum, Germany (GRID:grid.5570.7) (ISNI:0000 0004 0490 981X); Cluster of Excellence RESOLV, Bochum, Germany (GRID:grid.517297.f)